TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23702146

Group type: EXPERIMENTAL
Intervention: Dietary counseling plus administration of a commercially available Ca(2+) and VitD supplementation product
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dietary counseling alone
Number of subjects: 150
Study: 21244348

Group type: EXPERIMENTAL
Intervention: AD patient management program (PLASA study)
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1131

Group type: COMPARATOR
Intervention: LOCF analysis
Number of subjects: 1131

Group type: EXPERIMENTAL
Intervention: Multiple imputation, longitudinal mixed effects models, z-score LOCF
Number of subjects: 1131
Study: 19154992

Group type: EXPERIMENTAL
Intervention: Integrated Supported Employment (ISE) program
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Individual Placement & Support (IPS)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 163
Study: 17216347

Group type: EXPERIMENTAL
Intervention: FF-MAS 5 microM
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: FF-MAS 20 microM
Number of subjects: 365

Group type: COMPARATOR
Intervention: Inert control
Number of subjects: 365
Study: 15530627

Group type: EXPERIMENTAL
Intervention: Universal assessment
Number of subjects: 43219

Group type: EXPERIMENTAL
Intervention: Management by geriatric team
Number of subjects: 43219

Group type: COMPARATOR
Intervention: Targeted assessment
Number of subjects: 43219

Group type: COMPARATOR
Intervention: Management by primary-care team
Number of subjects: 43219
Study: 11396283

Group type: EXPERIMENTAL
Intervention: High volume BAL (mean volume: 131 +/- 14 ml)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low volume BAL (40 ml volume for all patients)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both high volume and low volume BAL
Number of subjects: 37
Study: 9632272

Group type: EXPERIMENTAL
Intervention: Peripheral blood progenitor cell transplantation (PBPCT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 66
Study: 8143994

Group type: EXPERIMENTAL
Intervention: Wheat bran supplement (13-15 g for 8 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oat bran supplement (13-15 g for 8 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Corn bran supplement (13-15 g for 8 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 48
Study: 3175057

Group type: EXPERIMENTAL
Intervention: Married client
Number of subjects: 43

Group type: COMPARATOR
Intervention: Unmarried client
Number of subjects: 43
Study: 31554005

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 314

Group type: COMPARATOR
Intervention: Naftopidil 75 mg
Number of subjects: 314
Study: 28606893

Group type: EXPERIMENTAL
Intervention: Feel the ViBe (FtV) + usual care
Number of subjects: 93

Group type: COMPARATOR
Intervention: Minimally enhanced usual care
Number of subjects: 93
Study: 25913022

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (target temperature, 33.0°C)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Therapeutic normothermia (target temperature, 36.8°C)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 295

Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 295
Study: 23265177

Group type: EXPERIMENTAL
Intervention: SSCT (Single-source CT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HPCT (High-pitch CT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DECT (Dual-energy CT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: SSCT vs DECT
Number of subjects: 180

Group type: COMPARATOR
Intervention: HPCT vs DECT
Number of subjects: 180
Study: 21699796

Group type: EXPERIMENTAL
Intervention: RFSP slope ≥ 0.2 in group A (95 patients, 27.6%)
Number of subjects: 457

Group type: COMPARATOR
Intervention: RFSP slope < 0.2 in group A (249 patients, 72.4%)
Number of subjects: 457
Study: 18083750

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no atorvastatin treatment)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All patients (combined analysis)
Number of subjects: 33
Study: 15806046

Group type: EXPERIMENTAL
Intervention: rTMS (110% motor threshold; 1 Hz; 2000 stimuli/day over 5 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham stimulation (placebo control)
Number of subjects: 14
Study: 12691821

Group type: EXPERIMENTAL
Intervention: Re-irradiation with 17 fractions of 1.8 Gy, 5 days a week (N=15, group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Re-irradiation with 4 Gy plus two fractions of 3 Gy the 1st week and six fractions of 3 Gy given every second day (N=15, group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of radiation schedules between group A and group B
Number of subjects: 30
Study: 10426972

Group type: EXPERIMENTAL
Intervention: Plastic valvulotome
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metal valvulotome
Number of subjects: 20
Study: 7568860

Group type: EXPERIMENTAL
Intervention: ioversol, 320/150/48
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: iohexol, 300/150/45
Number of subjects: 111

Group type: COMPARATOR
Intervention: ioversol, 320/100/32
Number of subjects: 111

Group type: COMPARATOR
Intervention: ioversol, 300/100/30
Number of subjects: 111
Study: 2306750

Group type: EXPERIMENTAL
Intervention: Flunarizine 10-15 mg (mean dose of 13 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nifedipine 10 mg (single dose)
Number of subjects: 7
Study: 6254720

Group type: EXPERIMENTAL
Intervention: 0.2 mg intravenous clonidine after pretreatment with 300 mg cimetidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.2 mg intravenous clonidine after pretreatment with 0.8 mg naloxone
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.2 mg intravenous clonidine after pretreatment with saline
Number of subjects: 6
Study: 30982411

Group type: EXPERIMENTAL
Intervention: Dual-task training (high-difficulty and low-difficulty)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dual-task training (high-difficulty)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 50
Study: 29779961

Group type: EXPERIMENTAL
Intervention: Perioperative discussion and review of images (CT image or angiogram)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard perioperative discussion
Number of subjects: 51
Study: 27224454

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) regimens for prevention of mother-to-child transmission during breastfeeding
Number of subjects: 677

Group type: COMPARATOR
Intervention: Urban location
Number of subjects: 677

Group type: COMPARATOR
Intervention: Salaried employment or being a student
Number of subjects: 677

Group type: COMPARATOR
Intervention: Infant hospitalization before weaning
Number of subjects: 677
Study: 25012765

Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day in 3 divided doses) + Raloxifene (120 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Risperidone (6 mg/day in 3 divided doses) + Placebo
Number of subjects: 46
Study: 22210632

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 4996

Group type: COMPARATOR
Intervention: Control (uncircumcised men)
Number of subjects: 4996

Group type: COMPARATOR
Intervention: Control (circumcised men)
Number of subjects: 4996
Study: 20483042

Group type: EXPERIMENTAL
Intervention: Adalimumab therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 8

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 8
Study: 17909753

Group type: EXPERIMENTAL
Intervention: Butorphanol (0, 6, or 12 mg/70 kg, i.m.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Naltrexone (0, 1, 3, 10, or 30 mg, p.o.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naltrexone pretreatment with Butorphanol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Naltrexone (various doses)
Number of subjects: 10
Study: 16441799

Group type: EXPERIMENTAL
Intervention: co-phenylcaine (lignocaine 5% with phenylephrine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: lignocaine 5% spray
Number of subjects: 30
Study: 14595042

Group type: COMPARATOR
Intervention: Conventional CPAP
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: IF CPAP
Number of subjects: 162
Study: 11247401

Group type: EXPERIMENTAL
Intervention: Asymmetric respiratory exercises method applied for 24 days
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (healthy children living in Upper Silesia industrial region)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Asymmetric respiratory exercises method
Number of subjects: 124
Study: 8612105

Group type: EXPERIMENTAL
Intervention: Exercise program over 22 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 160
Study: 1451713

Group type: COMPARATOR
Intervention: DoBe (L-Dopa + benserazide)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: DoBeBro (L-Dopa + benserazide + bromocriptine)
Number of subjects: 587
Study: 6144317

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 31141551

Group type: EXPERIMENTAL
Intervention: Instruments used to assess the quality of clerkship rotations from the perspective of students
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Instruments containing questions about the ethical domain
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Questions about negative experiences concerning the ethical domain
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Questions about witnessing patient mistreatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Questions about mistreatment against students
Number of subjects: 49
Study: 30121018

Group type: EXPERIMENTAL
Intervention: Successful decongestion by hemodynamics (right atrial pressure ≤8 mmHg and/or wedge pressure ≤15 mmHg at discharge)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Successful decongestion by clinical exam (≤1 sign of congestion at discharge)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Successful decongestion by hemoconcentration (any increase in hemoglobin)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Successful decongestion by estimated plasma volume (5% reduction in plasma volume)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: In-hospital worsening renal function (WRF) among patients decongested at discharge
Number of subjects: 433
Study: 28717702

Group type: EXPERIMENTAL
Intervention: Oral glutamine once per day
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (negative control subjects)
Number of subjects: 162
Study: 25128835

Group type: EXPERIMENTAL
Intervention: NCS-sweetened beverage
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sugar-sweetened beverage
Number of subjects: 3

Group type: COMPARATOR
Intervention: Unsweetened beverage
Number of subjects: 3
Study: 22189186

Group type: EXPERIMENTAL
Intervention: NIRS sensor pads placed over the dorsal, volar, and mobile wad compartments of the forearm during muscle contraction
Number of subjects: 63

Group type: COMPARATOR
Intervention: Contralateral forearm monitored as an internal control
Number of subjects: 63
Study: 20347838

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 18645193

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1,000 mg)
Number of subjects: 21
Study: 15909176

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 3000 shocks of 0.20 mJ/mm(2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional non‐operative measures (control group)
Number of subjects: 68
Study: 12877888

Group type: EXPERIMENTAL
Intervention: Aprotinin (APRO) at a low dose of 2 Mio KIU in the priming volume
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Aprotinin (NOAPRO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aprotinin (APRO)
Number of subjects: 30
Study: 10360185

Group type: EXPERIMENTAL
Intervention: Multidrug therapy with a protease inhibitor
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: No multidrug therapy with a protease inhibitor
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Tritherapy antiretroviral regimens
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Virological efficacy defined as undetectable viral load
Number of subjects: 483
Study: 7740525

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (3.4 g eicosapentaenoic and docosahexaenoic acids per day) for six months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no omega-3 PUFAs)
Number of subjects: 56
Study: 2139385

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/die)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Flunarizine (10 mg/die)
Number of subjects: 38
Study: 7234470

Group type: EXPERIMENTAL
Intervention: brief care (acute treatment aimed at effecting the patient's discharge after about a week)
Number of subjects: 224

Group type: COMPARATOR
Intervention: standard care (length of stay determined by the clinical team)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: brief care
Number of subjects: 224

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 224
Study: 29803597

Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization (L group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laparoscopic stripping (S group)
Number of subjects: 30
Study: 29291505

Group type: EXPERIMENTAL
Intervention: Alcoholic drinks targeting a BAC of 0.05%
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 61
Study: 26703889

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg per day
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 24406108

Group type: EXPERIMENTAL
Intervention: Endovascular approach (transvenous)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Epicardial approach (robotic-assisted)
Number of subjects: 21
Study: 22136068

Group type: EXPERIMENTAL
Intervention: NVP XR 400 mg once daily
Number of subjects: 443

Group type: COMPARATOR
Intervention: NVP IR 200 mg twice daily
Number of subjects: 443
Study: 19927011

Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 210

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 210
Study: 17966175

Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% applied twice daily for up to 12 months
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Dapsone gel 5%
Number of subjects: 486
Study: 15910714

Group type: EXPERIMENTAL
Intervention: Mild perioperative hypothermia
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normothermic patients
Number of subjects: 140
Study: 11854120

Group type: EXPERIMENTAL
Intervention: Fibrillin-1 genotype (2-3 genotype)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Fibrillin-1 genotype
Number of subjects: 145
Study: 10334524

Group type: EXPERIMENTAL
Intervention: Single-agent drugs (trimetrexate, melphalan, amonafide, carboplatin, or elsamitrucin) followed by CAF
Number of subjects: 365

Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Single-agent drugs followed by CAF
Number of subjects: 365

Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 365
Study: 8960857

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive drug therapy
Number of subjects: 950

Group type: COMPARATOR
Intervention: Moderate antihypertensive drug therapy
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Nisoldipine (calcium channel blocker)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin‐converting‐enzyme inhibitor)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive therapy
Number of subjects: 950

Group type: COMPARATOR
Intervention: Moderate antihypertensive therapy
Number of subjects: 950
Study: 1661765

Group type: COMPARATOR
Intervention: Atenolol (50 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Enalapril (10 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Verapamil (240 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 14
Study: 6761595

Group type: EXPERIMENTAL
Intervention: CMFV (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine)
Number of subjects: 236

Group type: COMPARATOR
Intervention: CD (carminomycin, dibromodulcitol)
Number of subjects: 236

Group type: COMPARATOR
Intervention: CMFV to CD crossover
Number of subjects: 236

Group type: COMPARATOR
Intervention: CD to CMFV crossover
Number of subjects: 236

Group type: COMPARATOR
Intervention: CD combination
Number of subjects: 236
Study: 30415307

Group type: EXPERIMENTAL
Intervention: Awareness Index of antibiotic resistance
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Antibiotic conservation practices
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ethical awareness of veterinarians
Number of subjects: 48
Study: 29415687

Group type: EXPERIMENTAL
Intervention: STAK-D intervention
Number of subjects: 13
Study: 26691608

Group type: EXPERIMENTAL
Intervention: School-based child oral hygiene program
Number of subjects: 120
Study: 24067296

Group type: EXPERIMENTAL
Intervention: Digoxin 0.125 mg/day
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Digoxin ≥ 0.25 mg/day
Number of subjects: 631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Digoxin overall
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Digoxin for cardiovascular causes
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Digoxin for heart failure causes
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Digoxin for unstable angina causes
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Digoxin in younger patients
Number of subjects: 631
Study: 23257098

Group type: EXPERIMENTAL
Intervention: Whole Lung Lavage (WLL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 20854139

Group type: EXPERIMENTAL
Intervention: Bedtime administration of ≥1 hypertension medications
Number of subjects: 2156

Group type: COMPARATOR
Intervention: Conventional therapy (all medications ingested upon awakening)
Number of subjects: 2156
Study: 17931286

Group type: EXPERIMENTAL
Intervention: Minimal nutrition intervention (personalized, face-to-face feedback with educational materials)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 203
Study: 16301225

Group type: EXPERIMENTAL
Intervention: Thermodilution at PaCO2 of 40 mmHg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thermodilution at PaCO2 of 30 mmHg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transesophageal Doppler at PaCO2 of 40 mmHg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transesophageal Doppler at PaCO2 of 30 mmHg
Number of subjects: 30
Study: 12077744

Group type: EXPERIMENTAL
Intervention: Obese patients with type 2 diabetes
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonobese patients with type 2 diabetes
Number of subjects: 70
Study: 11154484

Group type: EXPERIMENTAL
Intervention: Endoscopic Balloon Dilation (EBD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Endoscopic Balloon Dilation (EBD) and Endoscopic Sphincterotomy (EST)
Number of subjects: 34
Study: 9596232

Group type: EXPERIMENTAL
Intervention: Regular alcohol intake (<50 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heavy alcohol consumption (>=100 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular alcohol intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occasional drinking (less than once a week)
Number of subjects: 0
Study: 7508804

Group type: EXPERIMENTAL
Intervention: Standard treatment plus intravenous infusion of the prostacyclin analogue iloprost for 6 h per day over 14-21 days
Number of subjects: 713

Group type: COMPARATOR
Intervention: Standard postoperative treatment
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Standard treatment plus intravenous infusion of the prostacyclin analogue iloprost
Number of subjects: 713
Study: 3128439

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (3 mg/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 12
Study: 20804228

Group type: EXPERIMENTAL
Intervention: Family history (FHx) collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive interventions (mammography and fecal occult blood testing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FHx-based risk information
Number of subjects: 0

Group type: COMPARATOR
Intervention: FHx-based breast cancer risk information
Number of subjects: 0
Study: 720134

Group type: EXPERIMENTAL
Intervention: Urea preparations under occlusive dressings
Number of subjects: 35
Study: 31392958

Group type: EXPERIMENTAL
Intervention: Simple dressing
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Glue-as-a-dressing (tissue adhesive)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: No dressing
Number of subjects: 394

Group type: COMPARATOR
Intervention: All dressing strategies
Number of subjects: 394

Group type: COMPARATOR
Intervention: SSI questionnaire
Number of subjects: 394
Study: 29553965

Group type: EXPERIMENTAL
Intervention: Squatting position with ergonomic ankle support
Number of subjects: 168

Group type: COMPARATOR
Intervention: Comparison Group B (semirecumbent)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Comparison Group A (unsupported squatting)
Number of subjects: 168
Study: 27356083

Group type: EXPERIMENTAL
Intervention: DHA 20 mg/kg/d + ARA 40 or 60 mg/kg/d + ARA 120 mg/kg/d
Number of subjects: 30
Study: 24512385

Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28